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Introduction
Upon activation, platelets are able to release contents from three types of granules; α-granules, dense granules and lysosomes. α-Granules contain a vast variety of proteins involved in coagulation, adhesion, inflammation, cell growth and host defence [1] . The dense granules contain small molecules including Ca 2+ , ADP, ATP and serotonin, which are involved in secondary activation and recruitment of additional platelets [2] . Lysosomes are ubiquitous intracellular organelles with an acidic interior containing a large number of hydrolytic enzymes.
In contrast to the rather simplified view of lysosomes as waste bags for damaged macromolecules and organelles, today we recognize lysosomes as advanced organelles that are involved in many cellular processes and act as crucial regulators of cell homeostasis [3] .
Furthermore, lysosomes are known to play a role in both apoptosis and necrosis [4] [5] [6] . The lysosomal membrane is traversed by highly glycosylated transmembrane proteins including the lysosomal associated membrane proteins (LAMPs). Febbraio and Silverstein showed that the luminal part of LAMP-1 is exposed on the platelet surface upon platelet activation, indicating that lysosomes are secreted under certain conditions [7] . An increased release of the lysosomal enzyme platelet acid phosphatase was also reported in response to several platelet agonists including collagen, thrombin and immune complexes [8] . Following platelet activation, dense granules are the most rapidly secreted followed by α-granules and lysosomes. While α-granules and dense granules can reach close to 100% secretion, lysosomes do not show complete secretion even upon stimulation with strong agonists [2, 9, 10] .
Recently it was shown that lysosomal exocytosis in platelets is dependent on syntaxin binding protein 5, which interacts with the secretory complex proteins [11] . In human volunteers inflicted with a wound to estimate bleeding time, the activated platelets showed surface expression of LAMP-1, LAMP-2 and LIMP (LAMP-3, CD63), indicating that lysosomal exocytosis occur "in vivo" [9] . The role of lysosomal exocytosis in platelets is, however, still unclear. It has been suggested to be involved in the clearance of thrombi, vessel wall remodelling and modulation of platelet membrane proteins [9, 12] . Moreover lysosomal exocytosis could play a role in adhesion, since expression of LAMP-l is observed on cells with increased adhesive capacity, such as transformed cells of high metastatic potential, and interestingly, on embryonic cells [13] . Exocytosis of proteolytic lysosomal enzymes may also be beneficial for host defence [14] . Noteworthy, Coorssen et al [15] found that a Ca
2+
-triggered exocytosis of intracellular vesicles (later suggested to be lysosomes [16] ) led to a 20-30% increase in the surface area of Chinese hamster ovary cells.
Adhesion and aggregation of platelets at the site of vascular injury is essential for hemostasis and thrombosis and is mediated through receptors and release/production of different mediators. The major platelet agonist thrombin activates human platelets via the protease activated receptors (PAR) 1 and 4. Thrombin binds to the PARs and cleaves the N-terminal of the receptors, autoactivation then occurs when the new exposed N-terminal binds to the active site of the receptor ( [17, 18] and reviewed in [19] ). Furthermore, the effect of platelet activators is enhanced through positive feedback loops: e.g. the formation of thromboxane A2 (TXA2) and the secretion of ADP [20] .
Prostaglandin I2 (PGI2, also called prostacyclin) and nitric oxide (NO) are molecules physiologically important for suppressing platelet activation and platelet-vessel wall interaction. They are secreted from the vascular endothelium and act in a paracrine manner [21] .
PGI2 and NO do not only inhibit platelet activation, they also synergistically reverse platelet aggregation [22] which is important to maintain blood fluidity and minimize thrombus formation.
In this study, we have investigated the kinetics and magnitude of lysosomal exocytosis from human platelets and its regulation. We found that only a subpopulation of platelets responds to activation by lysosomal exocytosis as detected by LAMP-1 exposure on the platelet surface.
Lysosomal exocytosis, determined as N-acetyl-β-glucosaminidase (NAG) activity or LAMP-1 exposure, was dependent on secondary activation by ADP and was controlled by the endothelial derived inhibitors NO and PGI2.
Materials and methods

Chemicals and antibodies
The chemicals used were as follows: S-Nitroso-N-acetyl-DL-penicillamine (SNAP) 
Platelet isolation
Heparinized blood was mixed with acid citrate/dextrose solution (ACD, 5:1) and centrifuged (220 g for 20 min) to obtain platelet-rich plasma (PRP). The supernatant was collected and supplemented with apyrase (1 U/ml) and PGI2 (0.5 µg/ml), and centrifuged at 480 g for 20 min.
The platelet pellet was gently washed and resuspended in calcium free Krebs-Ringer glucose phosphate buffer (KRG) and counted.
Inhibitors
When indicated, platelets were pretreated with ASA (100 µM, 15 min), cangrelor (5 µM, 5 min), SNAP (10 or 30 µM; 2 min), PGI2 (1 µM; 2 min) or the solvent DMSO (final concentration 0.1-0.3%). None of these substances had any effect on lysosomal exocytosis when added alone (data not shown).
Analysis of lysosomal exocytosis by N-acetyl-β-glucosaminidase activity
The platelet suspension (3 x 10 8 /ml) was incubated with 1 mM CaCl2 for 5 min at 37°C.
Platelets were then stimulated with thrombin for 1 or 5 min after which activation was stopped by addition of ACD (1/100 dilution), hirudin (2 U/ml) and PGI2 (0.5 µg/ml), followed by centrifugation at 800 g for 10 min. The supernatants were collected and incubated at 37°C for 40 min in 0.2 M citrate buffer (pH 4.5) containing 0.8 mM 4-methylumbelliferyl N-acetyl-D-β-glucosaminide [23] . Fluorescence from methylumbelliferyl released by the enzyme was determined using a Victor Wallac multilabel plate reader (PerkinElmer) at λex 356 and λem 444 nm. NAG release was expressed as a fraction of the total NAG activity, which was obtained by lysis of all platelets in 1% Triton-X-100.
Analysis of LAMP-1 and P-selectin by flow cytometry
Citrated whole blood or PRP (obtained by centrifugation at 220 g, 20 min) was diluted (final dilution 1:5) in a mastermix, containing 2 mM GPRP to avoid fibrin polymerisation, thrombin of dense granules as well [24, 25] .
To study activation induced by stimulation of the platelet thrombin receptors PAR1 and PAR4 separately and in combination, an experimental system of low, medium or high level of platelet activation was designed. Thus, agonist concentrations were selected to achieve a P- The flow cytometry analysis was performed on 10 000 platelets per sample using log forward scatter (FS) and log FL2, where FL2 corresponded to detection of GPIIb-PE, i.e. all plateletderived particles. All data was further analysed using the Kaluza TM software (Beckman Coulter). To determine the expression of different markers, gates were placed using isotype control antibodies with matching fluorescence intensity and concentration as a reference to set the background to 1-2%. Samples showing more than 15% spontaneous expression of P-selectin were excluded from analysis.
Analysis of platelet aggregation and ATP release
Platelet aggregation was measured by analysis of changes in light transmission using a
Chronolog Dual Channel lumi-aggregometer (Chrono-log Corporation, Haverston, PA, USA)
according to the instruction of the manufacturer. Before each assay, the platelet suspension (3 x 10 8 /ml) containing 1 mM CaCl2 was incubated in the aggregometer for 5 min at 37°C under continuous stirring at 900 rpm. Thrombin was added and the aggregation response was followed for 10 min, which corresponded to maximal aggregation. Aggregation is expressed as percentage light transmission compared with KRG alone (=100%). In parallel, ATP secretion was measured using the Chrono-Lume® kit (Chrono-log Corporation) and the ATP concentration was calculated by an exogenously added ATP standard.
Statistical analysis
Data are expressed as means ± standard error of the mean (SEM). For statistical analysis paired t-tests were used when two groups were compared. When several groups were compared, oneway or repeated measures ANOVA followed by Dunnett's multiple comparison test against control or Bonferroni's multiple comparison tests was used. A p-value < 0.05 was considered significant. Data were analysed using GraphPad Prism TM (GraphPad Software, San Diego, CA). were carried out using thrombin.
Results
Lysosomal
To investigate the regulation of thrombin-induced lysosomal exocytosis in platelets, we inhibited cyclooxygenase using ASA and the ADP-receptor P2Y12 by addition of cangrelor. We found a significant inhibition of NAG release and LAMP-1 surface expression when cangrelor or a combination of the inhibitors was used, while ASA alone did not show a significant effect ( Figure 3A and B) . Prolonging the thrombin stimulation to 5 min (NAG release) or 10 min (LAMP-1 surface expression) did not alter the inhibitory effect of the inhibitors (Supplementary Figure S3) . As cangrelor prevents the secondary ADP-induced activation of platelets, we also tested the effect of ADP alone. Activation with ADP (5 µM, 10 minutes) resulted in 16±3%
LAMP-1 exposure as compared to 1.5±0.2% in control samples and 60±2% in response to thrombin (1 U/ml, 10 min) (mean±SEM, n=11). The corresponding expression of P-selectin was 95±1 (ADP), 11±2 (control) and 99±0 (thrombin). Platelet aggregation and ATP-secretion in response to thrombin were not affected by either cangrelor or ASA, whereas a slight but significant decrease in P-selectin expression was observed in the presence of cangrelor (1 min; Figure 3C -E).
Addition of the cyclic AMP (cAMP)-elevating eicosanoid PGI2 significantly prevented lysosomal exocytosis from platelets stimulated with thrombin ( Figure 4A and B). Addition of SNAP prevented NAG release from isolated platelets ( Figure 4A ), but did not cause any reduction of LAMP-1 surface expression in diluted whole blood (Supplementary figure S4A) .
We hypothesized the lack of effect of SNAP in diluted whole blood samples to be due to scavenging of NO by hemoglobin. These experiments were therefore repeated using PRP, 
Discussion
Our data show that high doses of thrombin or combined PAR1/4-AP only provoke partial lysosomal release, even at conditions where all platelets show α-granule release (P-selectin exposure). This is in accordance with previous findings [9, 10, 26] . Thrombin-induced NAG release was around 25% of total NAG activity, while the fraction of LAMP-1 positive platelets was 35-45% at a similar stimulation. The NAG release was rapid and no increase over time was found, similar to what was reported by Holmsen et al [26] , whereas LAMP-1 exposure increased slowly at extended stimulation. One potential explanation to this discrepancy may be that some NAG activity is lost during extended incubation times. Thrombin activates human blood platelets through binding, cleavage and activation of PAR1-and PAR4 receptors. In our study, stimulation with PAR1-AP or PAR4-AP induced similar levels of LAMP-1 expression upon stimulation, demonstrating that both receptors can be used to induce lysosomal exocytosis.
However, according to our flow cytometric analysis, only a fraction of the platelets responded to thrombin receptor activation with lysosomal secretion, suggesting that only a sub-population of platelets will respond with lysosomal release. Whether lysosomal exocytosis is the only characteristic shared within this sub-population of platelets remains to be determined.
It is well established that the effect of the primary platelet activators is enhanced by positive feedback loops. Release of TXA2 and ADP are the most characterized secondary autocrine activators and we found that pre-treatment of platelets with the ADP P2Y12 receptor antagonist cangrelor significantly decreased thrombin-induced lysosomal exocytosis.
A reduction in NAG release has previously been found upon pre-incubation of platelets with the ADP-removing system, creatine phosphate/creatine phosphokinase [27] . Moreover, we observed that thrombin-induced aggregation was not reduced by cangrelor. This is in line with previous findings showing that aggregation induced by high doses of thrombin is independent of the secondary ADP release [28] . Thrombin-induced PAR1 and PAR4 activation leads to long-lasting Gα12/13-and Gαq-mediated intracellular signaling whereas the secondary release of ADP and activation of P2Y12 contributes with Gαi-coupled signaling [29] .
Our results suggests that concomitant activation of Gα12/13-, Gαq-and Gαi-coupled receptors is important for efficient lysosomal secretion. In line with this, activation by ADP alone resulted in a modest but clear LAMP-1 expression whereas full P-selectin expression was seen. This further supports the notion that the signaling pathway synergy is important for efficient lysosomal exocytosis, while this is not required for release of α-granules. This is partly consistent with previous studies [7, 30] , reporting that ADP is a weak inducer of lysosomal exocytosis. However, due to differences in methodology and presentation of data, a complete comparison of the results is not possible. In this study, inhibition of TXA2 synthesis by ASA did not induce a significant alteration of lysosomal exocytosis. In common with PARs, the predominate TXA2 surface receptor TPα initiates Gαq-mediated signaling in platelets [29] .
This overlap in signaling pathways may explain why TXA2 plays no role when thrombin is present. This is in accordance with experiments performed by Vorland and Holmsen who found no effect on lysosomal secretion when using the specific TXA2 inhibitor SQ 29.548 in thrombin-stimulated platelets [27] and Chronos et al who compared the exposure of CD63 and P-selectin in healthy subjects before and after ingestion of ASA [31] . McKenzie et al reported that the spontaneous expression of LAMP-1, LIMP and P-selectin was reduced in platelets treated with ASA in vitro [32] . In contrast, we did not observe any effect of ASA on spontaneous lysosomal or α-granule exocytosis. However, as the spontaneous level of LAMP-1 and P-selectin expressions in both our and McKenzies studies are low (less than 10% of the platelets were positive for P-selectin), and the observed differences small (approximately 2% in McKenzie's study and 1% in our experiments), we believe that these discrepancies may as well be due to slight differences in pre-analytical handling. Either way the physiological relevance of such small variations can be questioned. Taken together, we conclude that the ADP/P2Y12 receptor signaling pathway is important for lysosomal exocytosis from thrombinactivated platelets, whereas TXA2 signaling is of minor importance.
There is a large body of evidence that endothelium-derived molecules effectively inhibit human platelets [21] . We found that treatment with PGI2 resulted in decreased lysosomal and α-granule exocytosis. In addition, PGI2 showed a slight, although not significant, inhibitory effect on thrombin-induced aggregation and dense granule secretion. ADP signalling through P2Y12 and Gαi causes a decrease in cAMP levels [33, 34] and this is opposed by PGI2 signalling via Gαs, which instead causes an increase in the cAMP levels. It is also well known that the PGI2/cAMP signalling pathway inhibits the agonist-induced rise in intracellular Ca 2+ [21] . As lysosomal exocytosis is dependent on intracellular Ca 2+ [14, 35] , it is likely that inhibition of PAR-induced Ca 2+ mobilization and subsequent ADP release represent one key target for the PGI2/cAMP signalling pathway.
In the present study, the NO-donor SNAP caused a profound reduction in platelet aggregation and prevented secretion of α-and dense granules as well as lysosomes. This was true even at the relatively high thrombin concentrations used in these experiments. It is notable that SNAP did not inhibit lysosomal release in diluted whole blood experiments, but had a pronounced effect in platelet-rich plasma and isolated platelet suspensions. The best available explanation is the presence of hemoglobin, which is an effective scavenger of NO, However, in vivo, the hemoglobin effect would normally be prevented by the formation of a red blood cell-free zone close to the endothelium [36] . Platelet inhibition by NO increases the levels of cGMP, which leads to a marked decrease in intracellular Ca 2+ [37] . This implies that inhibition of granule exocytosis and aggregation by NO and PGI2 may share a similar mechanism, which includes a reduction in secondary activation by decreased ADP release and inhibition of Ca 2+ -mobilization following PAR activation. From a broader perspective, our results indicate that endothelial platelet inhibitors such as NO and PGI2 easily can control platelet lysosomal secretion.
In conclusion, our study shows that lysosomal exocytosis occurs in a fraction of the platelets upon stimulation of the thrombin receptors PAR1 or PAR4, and that it involves functional positive feedback loops in terms of ADP release and activation of the P2Y12 receptor. We also conclude that lysosomal release, as well as other platelet activation events can be efficiently controlled by physiologically important platelet inhibitors such as NO and PGI2, even at relatively high thrombin concentrations, demonstrating the importance of a functional endothelium in the control of platelet granule release. For statistical analysis one-way ANOVA (A and B) or repeated measures ANOVA (C) was followed by Dunnett's multiple comparison tests against the control (0 U/ml). Significant differences are indicated by * p < 0.05, ** p < 0.01, *** p < 0.001 compared to control. In C, surface expression after 1 min vs. 10 min was compared using paired t-test. Significant differences are indicated by # p < 0.05, ## p < 0.01, ### p < 0.001. 
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